Lithium Toxicity — Written Clinical Reasoning

SAQ 1 — Chronic Lithium Toxicity Precipitated by Polypharmacy in an Elderly Woman (25 marks, 30 minutes)

Prompt: Outline your structured assessment and management of this patient, including the recognition and explanation of the precipitating drug interactions, the immediate toxicological management with reference to the EXTRIP criteria, the interpretation of the chronic end-organ effects, the approach to her renal and cardiovascular comorbidities, the discussion with the patient and family, and the longer-term plan for her mood disorder management. Justify each decision with reference to evidence and guideline recommendations. [1]

Model Answer

Framing and problem list (4 marks): [1]

This is acute-on-chronic lithium toxicity at 3.0 mmol per litre with significant neurological toxicity (GCS 13, ataxia, coarse tremor, myoclonus, slurred speech) and acute kidney injury (creatinine risen from 92 to 152), precipitated by the recent addition of three drugs that all increase lithium levels — indapamide (a thiazide-like diuretic), ibuprofen (an NSAID), and ramipril (an ACE inhibitor) — in a patient on a 25-year stable lithium regimen, with the additional background of lithium-related chronic end-organ effects (hypothyroidism, mild hypercalcaemia from probable lithium-induced hyperparathyroidism, and likely chronic interstitial nephritis given her baseline eGFR of 52). [1]

My structured problem list is:

1. Lithium toxicity (acute-on-chronic, level 3.0, with symptoms) — the immediate threat to life and brain function; meets the EXTRIP criteria for consideration of haemodialysis.
2. Acute kidney injury (creatinine 152, from baseline 92) — contributing to the reduced lithium clearance and requiring fluid and renal management.
3. QT prolongation (480 ms with T-wave flattening) — a cardiac conduction effect of lithium toxicity that carries a risk of arrhythmia.
4. The three precipitating drug interactions (indapamide, ibuprofen, ramipril) — all must be stopped and the mechanism understood to prevent recurrence.
5. Chronic lithium end-organ effects (hypothyroidism, hypercalcaemia, probable chronic interstitial nephritis) — requiring assessment and a longer-term management decision.
6. The underlying bipolar disorder — the indication for lithium must be addressed with the psychiatrist before any decision to restart. [1]

The precipitating drug interactions — pharmacological reasoning (5 marks): [1]

Three drugs were started simultaneously, all of which increase serum lithium levels through distinct but convergent mechanisms: [1]

• Indapamide (thiazide-like diuretic): Thiazides cause volume and sodium depletion at the distal tubule. The kidney compensates by increasing proximal tubular reabsorption of sodium, and because lithium is handled like sodium in the proximal tubule, lithium reabsorption increases in parallel. This typically raises the lithium level by 25 to 40 percent within days. This is the classic and most clinically important lithium drug interaction.
• Ibuprofen (NSAID): NSAIDs reduce renal prostaglandin production, which reduces renal blood flow and glomerular filtration, and increases proximal lithium reabsorption. All NSAIDs carry this risk, though indometacin is the most studied. The effect is additive to the thiazide effect.
• Ramipril (ACE inhibitor): ACE inhibitors reduce angiotensin II-mediated efferent arteriolar tone at the glomerulus, reducing the glomerular filtration pressure and the filtered load of lithium, and they alter proximal tubular handling to further increase lithium reabsorption. The effect builds over 1 to 4 weeks. [1]

The combination of all three, started without a lithium dose reduction or a level check, predictably precipitated toxicity. The correct approach when starting any of these drugs in a patient on lithium is to reduce the lithium dose by 25 to 50 percent and check a level within 5 to 7 days. This patient was a disaster waiting to happen, and the lesson for the discharge plan is the education of the patient, the GP, and the cardiologist about the lithium-interaction risk of these common cardiovascular and analgesic drugs. [1]

Immediate toxicological management (6 marks): [1]

1. Stop the lithium immediately and stop all three precipitating drugs (indapamide, ibuprofen, ramipril).
2. ABCDE assessment and supportive care. Her airway is at risk given her GCS of 13; I would nurse her in the recovery position and monitor her closely, with a low threshold for intubation if her conscious level deteriorates further. Continuous cardiac monitoring for the QT prolongation. Intravenous access.
3. Aggressive intravenous normal saline (0.9 percent sodium chloride) to restore intravascular volume, correct the AKI, and enhance renal lithium excretion. Lithium clearance tracks renal function and proximal sodium handling; volume expansion increases the GFR and suppresses the sodium avidity that drives proximal lithium reabsorption. I would give 1 to 2 litres over the first few hours, titrated to her volume status and her blood pressure (105/62, so she is not shocked but is relatively volume-depleted), then a maintenance rate adjusted to her urine output.
4. Do NOT give loop diuretics. Loop diuretics increase distal sodium delivery, which feeds back to increased proximal lithium reabsorption, paradoxically raising the level. Normal saline alone is the correct fluid.
5. Assess for haemodialysis using the EXTRIP criteria. This patient has a level of 3.0 mmol per litre (above 2.5) with significant symptoms (decreased consciousness at GCS 13, ataxia, myoclonus) and acute kidney injury with impaired renal function not responding immediately to fluids. Per the EXTRIP Workgroup consensus (Decker et al, 2015, PMID 25871131), extracorporeal treatment is recommended (grade 1D) for: a level above 4.0 regardless of symptoms; decreased level of consciousness, seizures, or life-threatening dysrhythmias irrespective of the level; and impaired kidney function with a level above 4.0. It is also suggested (grade 2D) for a level above 2.5 with significant confusion or a prolonged expected time to reduce the level below 1.0. This patient's level of 3.0 with her decreased consciousness and her AKI places her in the category where I would discuss urgent haemodialysis with the nephrology and toxicology teams, and I would have a low threshold to proceed, particularly if her level does not fall rapidly with saline or if her conscious level deteriorates. Intermittent haemodialysis is the preferred modality.
6. Monitor the serum lithium level every 2 hours until it is clearly falling and the patient is improving. Monitor the renal function, electrolytes, ECG, temperature, and neurological state continuously. [1]

Post-dialysis rebound management (2 marks): [1]

If she undergoes haemodialysis, I will check a post-dialysis rebound lithium level at 4 to 6 hours because lithium redistributes from the tissue compartment (which holds the vast majority of the body burden) back into the plasma after dialysis lowers the serum level. The level can rebound above the toxic threshold, and a repeat dialysis session may be required. The EXTRIP guidance is to obtain serial lithium measurements over 12 hours after stopping extracorporeal treatment. [1]

Interpreting the chronic end-organ effects (3 marks): [1]

• The mild TSH elevation (7.8 mU per litre) is consistent with her known lithium-related hypothyroidism (lithium accumulates in the thyroid and inhibits hormone synthesis; the McKnight meta-analysis found an odds ratio of 5.78 for clinical hypothyroidism). I would continue her levothyroxine (assuming she is on it) and recheck her thyroid function during the admission.
• The mild hypercalcaemia (2.62 mmol per litre) with the background of long-term lithium raises the possibility of lithium-induced hyperparathyroidism (lithium increases the set-point of the calcium-sensing receptor, producing inappropriately non-suppressed PTH). I would check a parathyroid hormone level and a 24-hour urinary calcium during the admission or at follow-up. The prevalence of lithium-associated hyperparathyroidism is around 4 to 6 percent.
• The baseline eGFR of 52 in a patient on lithium for 25 years is consistent with early lithium-induced chronic interstitial nephritis. This is now compounded by the acute kidney injury, and the trajectory of her renal function after recovery will inform the longer-term decision about her mood stabiliser. [1]

Approach to the renal and cardiovascular comorbidities (2 marks): [1]

Her AKI is multifactorial — the reduced lithium clearance from the three interacting drugs, the dehydration from her nausea and vomiting, and the background chronic interstitial nephritis. The intravenous normal saline will address the volume component and help the kidneys recover. Her heart failure and recent myocardial infarction mean that the fluid resuscitation must be monitored carefully — I would use a balanced approach with frequent clinical assessment and, if needed, a bedside ultrasound to assess the volume status. The ramipril is held for now; it will need to be reconsidered (with a lithium dose adjustment and a level check) once she has recovered, in discussion with her cardiologist. Her blood pressure medications need to be rationalised — I would discuss alternative antihypertensives that do not interact with lithium (amlodipine is a reasonable choice) with the cardiology team. [1]

Discussion with the patient and family (2 marks): [1]

Once she has recovered enough (or with her daughter as her surrogate), I would explain that her confusion and unsteadiness were caused by a toxic build-up of her lithium medication, which was precipitated by the three new medications she was started on for her blood pressure, her heart, and her knee pain — medications that are safe in most people but which interfere with the way the body clears lithium. I would explain that lithium has a very narrow safe range, that we have stopped the lithium and the interacting drugs, and that we are supporting her kidneys with intravenous fluids (and possibly a dialysis session to rapidly clear the lithium). I would reassure her that the intention is not to withdraw her psychiatric treatment, and that once she has recovered we will work with her psychiatrist to decide the best plan for her bipolar disorder going forward. [1]

Longer-term plan for the mood disorder (1 mark): [1]

The longer-term decision about her mood stabiliser must be made jointly with her treating psychiatrist. The options are: (1) restart lithium at a reduced dose with a lower target level (perhaps 0.5 to 0.6), with very close monitoring and a clear plan to avoid the interacting drugs; (2) switch to an alternative mood stabiliser such as valproate, lamotrigine, or an atypical antipsychotic; or (3) continue without prophylactic mood-stabilising therapy (the least favourable option given her history of bipolar I disorder with a high relapse risk). The decision will balance her psychiatric response history, her renal trajectory, her cardiovascular comorbidity, and her preferences. As the physician, my role is to provide the renal and endocrine assessment, to coordinate the monitoring, and to support the shared decision — not to make the psychiatric prescribing decision alone. [1]

SAQ 2 — The Dialysis Decision in Lithium Toxicity with Impaired Renal Function (10 marks, 15 minutes)

Prompt: A 68-year-old man on lithium for 20 years presents with chronic lithium toxicity. His serum lithium level is 3.4 mmol per litre. He is confused and drowsy but has had no seizures. His creatinine is 210 micromol per litre (baseline 130), and his eGFR is approximately 28 mL per minute. Outline the factors that determine whether he should receive haemodialysis, the EXTRIP criteria that apply to him, and your monitoring plan after dialysis. [1]

Model Answer

The dialysis decision — applying the EXTRIP criteria (4 marks): [1]

The EXTRIP Workgroup consensus (PMID 25871131) provides the evidence-based framework for the dialysis decision in lithium poisoning. The recommendation is based on integrating three factors: the serum lithium concentration, the clinical severity, and the renal function. For this patient: [1]

1. Serum level: 3.4 mmol per litre. This is above 2.5 (the severe toxicity threshold) but below 4.0 (the level at which dialysis is recommended regardless of symptoms). It falls in the range where the decision is guided by the clinical features and the renal function.
2. Clinical severity: confused and drowsy (decreased level of consciousness). The EXTRIP guidance recommends extracorporeal treatment (grade 1D) for decreased level of consciousness, seizures, or life-threatening dysrhythmias irrespective of the serum level. This patient's decreased consciousness alone meets a recommended indication for dialysis.
3. Renal function: eGFR 28 with an acute-on-chronic picture. Impaired kidney function that is not rapidly responding to intravenous fluids is a further indication, particularly with a level above 2.5. [1]

The conclusion: this patient meets the EXTRIP criteria for haemodialysis on the basis of his decreased level of consciousness (irrespective of the level) and his impaired renal function. I would commence intravenous normal saline immediately, involve the nephrology and toxicology teams urgently, and proceed to intermittent haemodialysis. Intermittent haemodialysis is the preferred modality; continuous renal replacement therapy is an acceptable alternative if haemodialysis is unavailable, but it clears lithium more slowly. [1]

Additional factors in the decision (2 marks): [1]

• The chronic pattern of toxicity. This is chronic accumulation toxicity (the tissue compartment is saturated), which is clinically more dangerous than acute overdose at the same level. This strengthens the case for dialysis — the brain tissue level is already toxic.
• The risk of SILENT. Prolonged or severe chronic toxicity carries the risk of the Syndrome of Irreversible Lithium-Effectuated NeuroToxicity, in which cerebellar and cognitive deficits persist after the serum level has normalised. Early and effective removal of the lithium is the best prevention.
• The cardiac risk. I would check an ECG for QT prolongation, which is common in lithium toxicity and which carries an arrhythmia risk; significant QT prolongation would further lower my threshold for rapid lithium removal. [1]

Monitoring plan after dialysis (4 marks): [1]

1. Post-dialysis rebound level at 4 to 6 hours. Lithium redistributes from the tissue compartment back into the plasma after dialysis, and the level can rebound above the toxic threshold. This is the rule, not the exception. The EXTRIP guidance is to obtain serial lithium measurements over 12 hours after stopping extracorporeal treatment.
2. Repeat haemodialysis if the level rebounds. If the post-dialysis level has risen significantly (for example, back above 2.0 with ongoing symptoms), a repeat session is indicated. Some centres use a continuous low-dose dialysis or CRRT after the initial intermittent session to blunt the rebound, particularly in the chronically toxic patient with a large tissue burden.
3. Continue the intravenous normal saline and the supportive care throughout, and monitor the renal function (the AKI should begin to recover as the lithium level falls and the volume is restored).
4. Monitor the clinical state (GCS, seizures, temperature, cardiac rhythm) continuously until the patient is clearly improving and the level is stably below 1.0 mmol per litre.
5. Once recovered, address the precipitant (the reason the lithium accumulated — typically a new drug, dehydration, or progressive CKD), and arrange a joint review with nephrology and psychiatry to decide whether to continue, dose-reduce, or switch the mood stabiliser. [1]